Boston Scientific Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael F. Mahoney
- Full Time Employees
- 59,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 300 Boston Scientific Way Marlborough MA United States of America 01752-1234
- IPO Date
- May 19, 1992
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.
Here Are Friday’s Top Wall Street Analyst Research Calls: Blackstone Mortgage, Boston Scientific, Edison International, Ford, GoDaddy, International Paper, Roblox, Saia, and More
Bank of America Corp DE Has $1.43 Billion Stock Holdings in Boston Scientific Corporation $BSX
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
Boston Scientific: Attempting The 2027 Reset
Boston Scientific Q2 Earnings Call Highlights
Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional Cardiology and Neuromodulation
Boston Scientific beats second quarter expectations, raises full-year outlook
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript
Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Boston Scientific Cuts Forecast on Product Slowdown and Competition
Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
Boston Scientific beats second quarter expectations, raises full-year outlook
Boston Scientific Cuts Outlook Ahead of Restructuring
Boston Scientific trims annual profit forecast on softer Watchman device demand
Is Boston Scientific Corp (BSX) Undervalued Despite Revenue of $5.442 Billion and EPS of $0.61? GF Score: 74/100, 56.5% Undervalued
Boston Scientific announces results for second quarter 2026
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More
Boston Scientific unveils new restructuring plan, expects job cuts